The crystal structure of fructose-1,6-bisphosphatase (EC 3.1.3.11) complexed with fructose 6-phosphate, AMP, and Mg2' has been solved by the molecular replacement method and refined at 2.5-A resolution to a R factor of 0.215, with root-mean-square deviations of 0.013 A and 3.5°for bond lengths and bond angles, respectively. No solvent molecules have been included in the refinement. This structure shows large quaternary and tertiary conformational changes from the structures of the unligated enzyme or its fructose 2,6-bisphosphate complex, but the secondary structures remain essentially the same. Dimer C3-C4 of the enzyme-fructose 6-phosphate-AMP-Mg2+ complex twists about 190 relative to the same dimer of the enzyme-fructose 2,6-bisphosphate complex if their C1-C2 dimers are superimposed on one another. Nevertheless, many interfacial interactions between dimers of C1-C2 and C3-C4 are conserved after quaternary structure changes occur. Residues of the AMP domain (residues 6-200) show large migrations of Ca atoms relative to barely significant positional changes of the FBP domain (residues 201-335).
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Fructose-1,6-bisphosphatase (Fru-1,6-Pase; D-fructose-1,6-bisphosphate 1-phosphohydrolase, EC 3.1.3.11), a key regulatory enzyme in gluconeogenesis, catalyzes the hydrolysis of fructose 1,6-bisphosphate to fructose 6-phosphate (F6P) and inorganic phosphate. Fru-1,6-Pase isolated from various sources consisted offour identical polypeptide chains that aggregate into a relatively flat tetramer (Fig. 1) . Seven complete amino acid sequences have been reported for Fru-1,6-Pases from various sources (1) (2) (3) (4) (5) (6) . Recently, threedimensional structures of the unligated Fru-1,6-Pase and of its complex with fructose 2,6-bisphosphate (Fru-2,6-P2) in the space group P3221 were described in detail (7, 8*) .
The catalytic and regulatory properties of the enzyme isolated from gluconeogenic tissues as well as other sources have been extensively studied (9, 10) . Omitting those forms that also have a phosphorylation site, the enzyme activity is regulated in vivo by Fru-2,6-P2 and AMP (9, 10) . Kinetic experiments controversially have suggested that Fru-2,6-P2 binds to the active site (11) , to an allosteric site (12), or to both (13) . On basis of the structures, we proposed that Fru-2,6-P2 binds to the active site (7, 8) . AMP is an allosteric inhibitor (14) , and its inhibition is synergistic with Fru-2,6-P2 (15, 16) .
We have grown cocrystals of the enzyme complexed with F6P, AMP, and Mg2+ in the space group P21212. This structuret has been solved by the molecular replacement method and shows large quaternary and tertiary conformational changes from the unligated structure or the structure of the enzyme-Fru-2,6-P2 complex. Here, we describe the F6P and AMP binding sites and large structural differences between the enzyme-F6P-AMP-Mg2+ complex and the enzyme-Fru-2,6-P2 complex. 
METHODS
Fru-1,6-Pase was purified from pig kidney as described (8) . It has an optimal activity at neutral pH. The neutral form of Fru-1,6-Pase was cocrystallized with 1 mM AMP, 1 mM F6P, and 5 mM MgCl2 by dialyzing a protein solution (10-15 mg/ml) against a buffer containing 20 mM Tris base, 2 mM maleic acid, 0.1 mM EDTA, 5 mM NaN3, and 9.5% (wt/vol) PEG (molecular weight = 3350) at pH 7.4. A 4-to 7-day dialysis yielded crystals with a typical size of 0.3 x 0.8 X 1.5 mm, which have the space group P21212 with unit cell dimensions of a = 61.6, b = 166.6, and c = 80.0 A. Two monomers exist in the crystallographic asymmetric unit.
The diffraction data were collected on the multiwire x-ray area detector at the Biotechnology Resource, University of Virginia (17) . A total of 87,690 measured diffraction maxima was reduced to 27,511 unique reflections with aRsym of 6.1%. These data are nearly complete to 2.5-A resolution and also include 856 reflections at higher resolution.
The recently refined structure of the enzyme-F6P complex (H.K. and W.N.L., unpublished results) in the space group P3221 was used to find the orientation of the enzyme-F6P-AMP-Mg2+ structure in the space group P21212. To do so, a dimer of the F6P structure was placed in a large artificial P1 cell in order to obtain structure factors; Crowther's cross rotation function (18) was then calculated for several resolution shells with different intensity cutoff values. These calculations for different shells consistently indicated the strongest peak at a = 450, , = 850, and y = -65°. The R-factor search was carried out by use of the translation function (19) for various resolution shells from 5 to 8 A. The correct solution from the R-factor search, which had the lowest R factor (0.405) for 606 reflections, was further distinguished from others by examination of lattice contacts by using the program FRODO (20) .
Taken as two rigid bodies, one for each monomer, the model from the molecular replacement was refined for 40 steps of energy minimization by using the program XPLOR (21) . This refinement decreased the R factor from 0.539 to 0.392 for 25, 402 reflections between 10.0-and 2.5-A resolution. This rigid body refinement showed a maximum of 5.4°o f rotation, which was different from that of the molecular replacement, and up to 30 of difference between relative rotation of two monomers. After the structure from the rigid body refinement was extensively rebuilt by using the program FRODO (20) , the R factor dropped to 0.364. Several cycles of simulated annealing refinement with XPLOR and manual rebuilding brought the R factor to 0.215, with root-mean-square deviations of 0.013 A and 3.5°for the bond lengths and bond angles, respectively. No solvent molecules have been included in the refinement.
RESULTS AND DISCUSSION Conformational Changes of the Enzyme-F6P-AMP-Mg2+
Complex. In spite of large quaternary and tertiary structure changes, the secondary structures of the enzyme-F6P-AMP-Mg2' complex remain essentially the same as those of the enzyme-Fru-2,6-P2 complex. Similar to the unligated structure ( Fig. 2) , we also find here that the loop of residues 54-67 and the N-terminal region (residues [1] [2] [3] [4] [5] in the structure of the F6P-AMP-Mg2+ complex show little or no electron density. Thus the loop of residues 54-67 might exist in multiple conformations, might be disordered, or might have been removed partially or completely by proteolytic cleavage. This region is proteolytically sensitive (22) . No significant cleavages were detected by microsequencing techniques in a solution prepared by redissolving our crystals. It is therefore most probable that this loop has multiple conformations or more extensive disorder.
In Fig. 3 shape of density since AMP has a purine base, which is much bigger than the hydroxyl group of F6P.
As shown in Fig. 5 (8) .
The proposed site or sites to which Fru-2,6-P2 binds to the enzyme include the active site (11), the allosteric site (12) , and both catalytic and allosteric sites (13) . Our x-ray diffraction studies indicate that Fru-2,6-P2 binds at the active site of the enzyme (7, 8 ). The present study shows that the 6-phosphate and sugar groups of F6P binds at the active site in positions that correspond to the 6-phosphate and ribose of Fru-2,6-P2 in our previous studies. E97, E98, D118, P119, L120, D121, G122, S123, S124, N125, N212, E213, G214, Y215, A216, A242, R243, Y244, V245, G246, S247, M248, V249, M263, Y264, P265, K269, S270, P271, K272, G273, K274, L275, R276, and E280. Except for Ala-242 and Arg-243 from the neighboring monomer, all other residues come from the same monomer. For an easy comparison that F6P and Fru-2,6-P2 have the same binding sites, the F6P site is plotted in a view similar to the Fru-2,6-P2 site (compare with figure 10 in ref. 8 , which actually appears as figure 13)*.
enzyme preparations. The enzyme used for the previous AMP complex was in some degree attacked by unknown proteases, but no significant cleavage was found for the material in this study by microsequencing techniques. Another interpretation is that an extra intermolecular contact at the major site in the space group P3221 ofthe early study (7) contributes to stronger binding of AMP at the major site as compared with the minor site. In the present study, in the space group P21212, there are no intermolecular interactions with AMP. Two sites per tetramer were reported for the AMP binding to the bovine liver enzyme (23, 24) , but additional sites were observed if the concentration of AMP was raised to 0.2 mM (25) . Four sites per tetramer were also observed (26) (27) (28) (29) . In the presence of substrate, occupation of these sites is enhanced (30, 31) . Our results, four sites per tetramer for AMP binding to the neutral form of the pig kidney enzyme (this study) and two sites for AMP binding to the partially proteolytically cleaved form (7) , are consistent with the kinetic observations that when the neutral form of the enzyme is subjected to proteolysis, the AMP inhibition is decreased or completely lost for the enzymes from rabbit liver (32) (33) (34) (35) (36) , rat liver (36) , chicken liver (37) , sheep liver (38) , and pig kidney (39) .
As shown in Fig. 6 , the phosphate group of AMP interacts with the backbone atoms of Glu-29 and Met-30 and side chain atoms of Thr-27, Lys-112, and Tyr-113 in both chains of the dimer. The side chain atoms ofTyr-113 in both chains are also in contact with the sugar ring of AMP. The purine base of AMP is located near the hydrophobic core of the enzyme, interacting with residues Val-17, Gln-20, Gly-21, Thr-31, and Met-177. In addition, Arg-140 is near the sugar ring of AMP.
The removal of residues 1-25 from pig kidney Fru-1,6-Pase results in the formation of an enzyme insensitive to AMP inhibition but that still turns over the substrate (40) . Our AMP binding geometry shows abundant contacts between AMP and residues Val-17 to Thr-31 in accordance with the above kinetic observation.
The ultraviolet difference spectrum of Fru-1,6-Pase induced by AMP showed maxima at 288 and 279 nm, which were interpreted as perturbations in the environment of tyrosine residues (41) . Our structures suggest that Tyr-113 may contribute to the spectral change. This tyrosine is conserved throughout all known sequences. In addition, residues Val-17, Met-30, Thr-31, and Met-177 show conservative variation. Arg-140 is conserved as either arginine or lysine in all AMP-binding Fru-1,6-Pases. Chemical modification of rabbit liver Fru-1,6-Pase with pyridoxal phosphate decreases its sensitivity to AMP inhibition; two lysyl residues were modified to the extent of -50% (42) . Comparative sequence analyses have indicated that residue 141, which is lysine in the pig kidney enzyme and leucine in the yeast enzyme, is not a good candidate for the AMP binding (3, 6, 43) ; this result is in agreement with our structure studies. -letter abbreviations) F16, V17, M18, E19, Q20, G21, R22, K23, A24,   R25, G26, T27, G28, E29, M30, T31, Q32, K112, Y113, Y139, R140, L159, V160, A161, In contrast to the active site residues, the conservation of amino acids in the AMP binding site is poor, perhaps because residues 17-31 interact with AMP mainly through backbone atoms. Hence, a mutation of one or more side chains may have less effect on the AMP binding. On the other hand, sequence variation may reflect different levels of AMP inhibition in various species of the enzyme. For instance, the AMP inhibition of Fru-1,6-Pase can vary significantly, ranging from Ki values below 1 ,uM for the rabbit skeletal muscle enzyme (44) , through 10-20 AM for the liver and kidney enzymes (45) , 80-200 ,uM for the yeast enzymes (46) , to no AMP inhibition for chloroplast (47, 48) and bumblebee flight muscle (49) enzymes.
Note Added in Proof. An additional sequence, from spinach chloroplast, has appeared (50) to supplement those sequences in refs. 1-6.
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